Guide
Mounjaro Side Effects: The Tirzepatide-Specific Pattern
Same molecule as Zepbound, so the adverse-event profile is the same: gastrointestinal effects clustering after each dose increase and easing at a stable dose. The tirzepa
Same molecule as Zepbound, so the adverse-event profile is the same: gastrointestinal effects clustering after each dose increase and easing at a stable dose. The tirzepatide pattern differs from semaglutide in reporting lower nausea and vomiting but comparatively more constipation.
What did the trials record?
| Event | Tirzepatide | Semaglutide | Note |
|---|---|---|---|
| Nausea | ~29% | ~44% | Lower on tirzepatide |
| Vomiting | ~13% | ~24% | Lower on tirzepatide |
| Diarrhoea | ~23% | ~30% | Lower on tirzepatide |
| Constipation | ~17% | ~24% | Comparable, and often the most persistent |
| Discontinued for an adverse event | 4.3–7.1% | ~7% | Similar |
Cross-trial comparison, not a head-to-head on tolerability. Different populations and titration schedules; treat the direction as indicative rather than the percentages as comparable.
Nausea and vomiting concentrate in the days after an increase and settle. Constipation is the one that tends to persist at a stable dose, and it is the effect patients most often report as the ongoing one rather than the initial one.
That distinction matters because a symptom that settles and a symptom that persists call for different conversations. Both are for a prescriber, not a web page.
Is Mounjaro's profile different from Zepbound's?
No. Same molecule, same manufacturer, same dose strengths. What differs is the approved indication and therefore the trial population — SURPASS studied type 2 diabetes, SURMOUNT studied weight management — which is why reported rates differ slightly between programmes without the drug differing at all.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
What are the most common Mounjaro side effects?
Gastrointestinal: nausea about 29%, diarrhoea about 23%, constipation about 17% and vomiting about 13% at the highest dose, clustering after each dose increase.
Is Mounjaro gentler than Ozempic?
Cross-trial figures report lower nausea and vomiting on tirzepatide, but these are different trials with different populations, not a head-to-head on tolerability.
Which side effect lasts longest?
Constipation tends to persist at a stable dose, where nausea and vomiting concentrate after an increase and settle.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Tirzepatide for Type 2 DiabetesResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Tirzepatide and Fatty Liver / MASHResearch
- Tirzepatide and Diabetes Prevention Over 176 WeeksJournal
- Tirzepatide and Chronic Kidney DiseaseResearch
- Tirzepatide and Cardiovascular OutcomesResearch
Related coverage
- Mounjaro for Weight Loss: The Same Molecule at Three Times the Price
- Nausea: what the trials recorded
- Hair loss: usually the weight loss
- Fatigue: three causes
- Constipation and the ileus line
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Tirzepatide and Sleep Apnea: Evidence and FDA Status
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial Shows
GLP-1 Tirzepatide Rank. “Mounjaro Side Effects: The Tirzepatide-Specific Pattern.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/mounjaro-side-effects-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.